HomeBUSINESS
BUSINESS

Kyowa Kirin Kicks Off Japan PIII for Regpara Follow-Up Evocalcet
(Nov.1.2017)

Kyowa Hakko Kirin said on October 30 that it has commenced a PIII open-label trial in Japan for the calcimimetic agent evocalcet (KHK7580) for the treatment of hypercalcemia in patients with parathyroid carcinoma or primary hyperparathyroidism ...
(LOG IN FOR FULL STORY)